Class Dismissed: US FDA’s ‘Dean’ Bob Temple Retiring After 52 Years

 
• By Michael McCaughan

Robert Temple, the US FDA’s most experienced drug regulator, is currently serving an emeritus role at the agency. The immediate impact of his departure will be mostly symbolic, but still unsettling.

The departure of Robert Temple, deputy CDER director for clincal science, marks the end of an era for the FDA. (File)
Michael McCaughan

Read more by Michael McCaughan

Michael McCaughan is a founding member of Prevision Policy LLC, a leading provider of regulatory and reimbursement policy analysis for the biopharma industry. He was previously the Editor-In-Chief of The Pink Sheet and remains a contributor to the publication.

More from US FDA

More from R&D